NCT06313008Completed
Empagliflozin Versus Vildagliptin in CAD Patients With T2DM
A Clinical Study Comparing Effects of Empagliflozin Versus Vildagliptin on Inflammatory Biomarkers, and Atrial Function in Coronary Artery Disease Patients With Type 2 Diabetes: EMBA-VILDA-Response Trial.
Source: ClinicalTrials.gov · Last updated 29 Nov 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
We compared the cardioprotective effects of empagliflozin, an SGLT2 inhibitor, with those of vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, focusing on various inflammatory biomarkers lipid profile, and cardiac function, in patients with type 2 diabetes mellitus (T2DM).
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 120 (actual)
- First submitted
- 9 Mar 2024
- Start date
- 10 Aug 2023
- Primary completion date
- 30 Sept 2024
- Lead sponsor
- Damanhour University
- Diseases
- Coronary artery disease, Type 2 diabetes
- NCT number
- NCT06313008
What you commit to
- Study type: Interventional
- Participants enrolled: 120
- From 10 Aug 2023 to the primary completion date, 30 Sept 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- patients with type 1 diabetes mellitus or secondary diabetes mellitus.
- patients with untreated cancer.
- patients with liver failure that was virus-, autoimmune- or drug-induced.
- patients allergic to empagliflozin or vildagliptin.
Lab values
- patients with left ventricular ejection fraction (LVEF) \< 30%.
- patients with anemia (hemoglobin \< 12 g/dL).
Other
- patients with renal dysfunction (estimated glomerular filtration rate \< 45 mL/min/1.73 m2).
- patients with hepatic cirrhosis.
- patients with alcoholism.
- pregnant or breastfeeding patients, or those planning to become pregnant during the course of the study.
Who the study is looking for
- T2DM patients with chronic stable angina.
- patients with glycated hemoglobin (HbA1c) levels of 6.0-10.0%.
- patients aged 20-80 years.
- patients with a body mass index of ≥ 22 kg/m2.
- patients who provided written informed consent.
Age in the registry: 40 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Rehab Hussein Werida Coordinator of this site? Confirm its status | Damanhūr | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.